130 related articles for article (PubMed ID: 2477908)
1. A phase II study of oral etoposide in elderly patients with small cell lung cancer.
Smit EF; Carney DN; Harford P; Sleijfer DT; Postmus PE
Thorax; 1989 Aug; 44(8):631-3. PubMed ID: 2477908
[TBL] [Abstract][Full Text] [Related]
2. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.
Girling DJ
Lancet; 1996 Aug; 348(9027):563-6. PubMed ID: 8774567
[TBL] [Abstract][Full Text] [Related]
3. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
Johnson DH; Greco FA; Strupp J; Hande KR; Hainsworth JD
J Clin Oncol; 1990 Oct; 8(10):1613-7. PubMed ID: 2170589
[TBL] [Abstract][Full Text] [Related]
4. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of oral VP-16-213 in small cell lung cancer.
Matsui Y; Oshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
Cancer; 1987 Dec; 60(12):2882-5. PubMed ID: 2824017
[TBL] [Abstract][Full Text] [Related]
6. The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer.
Clark PI; Cottier B
Semin Oncol; 1992 Dec; 19(6 Suppl 14):36-9. PubMed ID: 1336898
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.
Einhorn LH; Pennington K; McClean J
Semin Oncol; 1990 Feb; 17(1 Suppl 2):32-5. PubMed ID: 2154857
[TBL] [Abstract][Full Text] [Related]
8. Single-agent oral etoposide for elderly small cell lung cancer patients.
Carney DN; Grogan L; Smit EF; Harford P; Berendsen HH; Postmus PE
Semin Oncol; 1990 Feb; 17(1 Suppl 2):49-53. PubMed ID: 2154860
[TBL] [Abstract][Full Text] [Related]
9. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
10. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
Waits TM; Johnson DH; Hainsworth JD; Hande KR; Thomas M; Greco FA
J Clin Oncol; 1992 Feb; 10(2):292-6. PubMed ID: 1310104
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
Hainsworth JD; Stroup SL; Greco FA
Cancer; 1996 Jun; 77(12):2458-63. PubMed ID: 8640693
[TBL] [Abstract][Full Text] [Related]
12. [A phase II study of etoposide (NK 171) in small cell lung cancer--comparison of results between intravenous administration and oral administration].
Furuse K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2352-7. PubMed ID: 3000299
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
[TBL] [Abstract][Full Text] [Related]
16. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study.
Grunberg SM; Crowley J; Hande KR; Giroux D; Munshi N; Lau DH; Schroder LE; Zangmeister MH; Balcerzak SP; Hynes HE; Gandara DR
Cancer Chemother Pharmacol; 1999; 44(6):461-8. PubMed ID: 10550566
[TBL] [Abstract][Full Text] [Related]
17. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer.
Evans WK; Radwi A; Tomiak E; Logan DM; Martins H; Stewart DJ; Goss G; Maroun JA; Dahrouge S
Am J Clin Oncol; 1995 Apr; 18(2):149-55. PubMed ID: 7534977
[TBL] [Abstract][Full Text] [Related]
18. Chronic oral etoposide in non-small cell lung carcinoma.
Estapé J; Palombo H; Sánchez-Lloret J; Agustí C; Grau JJ; Daniels M; Viñolas N; Solá C; Biete A; Ramirez J
Eur J Cancer; 1992; 28A(4-5):835-7. PubMed ID: 1326308
[TBL] [Abstract][Full Text] [Related]
19. High-dose etoposide therapy for extensive small cell lung cancer: a Cancer and Leukemia Group B Study.
Luikart SD; Propert KJ; Modeas CR; Green MR; Perry MC
Cancer Treat Rep; 1987 May; 71(5):533-4. PubMed ID: 3032434
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M
Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
